- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL)
CUSIP: 55083R203
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 19,139,684
- Total 13F shares
- 6,818,719
- Share change
- +6,818,366
- Total reported value
- $60,295,418
- Put/Call ratio
- 71%
- Price per share
- $8.84
- Number of holders
- 62
- Value change
- +$60,292,297
- Number of buys
- 61
Quarterly Holders Quick Answers
What is CUSIP 55083R203?
CUSIP 55083R203 identifies LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q3 2025
Recent filing periods for CUSIP 55083R203:
Top shareholders of LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Robert Nelsen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
36,542,716
mixed-class rows
|
$83,020,992 | — | 14 Jun 2024 | |
| GSK plc |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
30,253,189
|
$68,977,271 | — | 21 Jun 2021 | |
| ARCH Venture Fund IX, L.P. |
13D/G
|
Robert Nelsen |
13%
|
36,597,716
|
$17,200,927 | $0 | 31 Dec 2024 | |
| Foresite Capital Fund IV, L.P. |
13D/G
|
James B. Tananbaum |
9.2%
|
27,161,892
|
$12,766,089 | +$3,611,010 | 31 Mar 2025 | |
| MWG Management Ltd. |
13F
|
Company |
105%
|
20,162,332
|
$10,847,335 | — | 31 Mar 2025 | |
| Hans Edgar Bishop |
3/4/5
|
Director |
—
mixed-class rows
|
4,815,614
mixed-class rows
|
$10,683,200 | — | 14 Jun 2024 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
83%
|
16,007,999
|
$8,612,303 | — | 31 Mar 2025 | |
| Orland Properties Ltd |
13F
|
Company |
78%
|
15,093,969
|
$8,150,743 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
4.5%
from 13D/G
|
12,721,571
|
$6,844,206 | — | 31 Mar 2025 | |
| Decheng Capital LLC |
13F
|
Company |
62%
|
11,909,341
|
$6,407,225 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
51%
|
9,737,729
|
$5,238,898 | — | 31 Mar 2025 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
42%
|
8,133,047
|
$4,375,579 | — | 31 Mar 2025 | |
| venBio Partners LLC |
13F
|
Company |
37%
|
7,102,190
|
$3,820,978 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
34%
|
6,478,836
|
$3,487,000 | — | 31 Mar 2025 | |
| Alphabet Inc. |
13F
|
Company |
30%
|
5,865,125
|
$3,167,168 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
23%
|
4,399,139
|
$2,367,263 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
23%
|
4,506,857
|
$2,350,849 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
19%
|
3,702,440
|
$1,991,913 | — | 31 Mar 2025 | |
| Richard Klausner |
3/4/5
|
Director |
—
mixed-class rows
|
4,071,199
mixed-class rows
|
$1,791,262 | — | 15 May 2025 | |
| HSG Holding Ltd |
13F
|
Company |
16%
|
3,045,997
|
$1,462,079 | — | 31 Mar 2025 | |
| Almitas Capital LLC |
13F
|
Company |
13%
|
2,482,606
|
$1,335,642 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
9.2%
|
1,768,500
|
$951,453 | — | 31 Mar 2025 | |
| MIC Capital Management UK LLP |
13F
|
Company |
9%
|
1,740,569
|
$936,426 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
8.3%
|
1,604,676
|
$863,316 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
6.7%
|
1,295,073
|
$696,750 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
5.2%
|
1,004,642
|
$540,497 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
4.5%
|
876,037
|
$471,307 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
4.5%
|
866,403
|
$466,125 | — | 31 Mar 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
4.3%
|
823,317
|
$442,945 | — | 31 Mar 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
|
Company |
4.3%
|
823,317
|
$442,945 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
3.4%
|
660,899
|
$354,000 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
3.3%
|
641,173
|
$344,951 | — | 31 Mar 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
3.1%
|
588,235
|
$316,470 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
2.9%
|
558,979
|
$300,731 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
2.7%
|
525,782
|
$282,871 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
2.7%
|
513,828
|
$276,439 | — | 31 Mar 2025 | |
| Clarius Group, LLC |
13F
|
Company |
2.1%
|
399,168
|
$214,752 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
2%
|
391,200
|
$210,466 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
2%
|
387,680
|
$208,572 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
2%
|
378,880
|
$203,838 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.9%
|
358,592
|
$192,922 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
1.5%
|
295,647
|
$159,058 | — | 31 Mar 2025 | |
| Cathy Friedman |
3/4/5
|
Director |
—
mixed-class rows
|
596,370
mixed-class rows
|
$158,093 | — | 15 May 2025 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
1.3%
|
246,349
|
$132,536 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
244,714
|
$131,656 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
1.2%
|
235,694
|
$126,793 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.2%
|
234,944
|
$126,400 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.1%
|
220,790
|
$118,785 | — | 31 Mar 2025 | |
| Matthew Lang |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
218,750
mixed-class rows
|
$114,000 | — | 10 Feb 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
1%
|
198,324
|
$106,698 | — | 31 Mar 2025 |
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) as of Q2 2025
As of 30 Jun 2025,
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,818,719 shares.
The largest 10 holders included
ARCH Venture Management, LLC, Foresite Capital Management IV, LLC, Almitas Capital LLC, venBio Partners LLC, VANGUARD GROUP INC, Foresite Capital Management V, LLC, PRICE T ROWE ASSOCIATES INC /MD/, Alphabet Inc., CITADEL ADVISORS LLC, and HSG Holding Ltd.
This page lists
62
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q4 2025 Across Filers
Q4 2025 holders
67
Q2 2025 holders
62
Holder diff
-5
| Investor | Q4 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.